Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Hamburg
Clinical trial register · Germany

Clinical Trials in Hamburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5087 matching records held by the registry are in this view. Synced 20 Nov 2026, 03:18 UTC
5087
Studies in scope
all four open statuses
2894
Recruiting now
open to new participants
991
Lead sponsors
across recruiting studies
Top sites
Berlin 117 Essen 60 Hamburg 54 Dresden 53 Cologne 49
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf76 AstraZeneca54 Janssen Research & Development, LLC32 Eli Lilly and Company31 Novartis Pharmaceuticals28 AbbVie26 Hoffmann-La Roche22 Bristol-Myers Squibb19 Merck Sharp & Dohme LLC16 Gilead Sciences15 Pfizer13 GlaxoSmithKline13 Sanofi12 Boehringer Ingelheim11 Novo Nordisk A/S11 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest10 Amgen10 Celgene10 Takeda8 Incyte Corporation8 Boston Scientific Corporation7 Daiichi Sankyo6 Exelixis6 Abbott Medical Devices6 ViiV Healthcare5 BioNTech SE5 Gaia AG4 Alexion Pharmaceuticals, Inc.4 Ipsen4 Martini-Klinik am UKE GmbH4 argenx4 Genmab4 JCR Pharmaceuticals Co., Ltd.4 Regeneron Pharmaceuticals4 Alfasigma S.p.A.4 European Organisation for Research and Treatment of Cancer - EORTC4 Asklepios proresearch4 Genentech, Inc.3 BioMarin Pharmaceutical3 UCB Biopharma SRL3 W.L.Gore & Associates3 AGO Research GmbH3 Italfarmaco3 Biogen3 Charite University, Berlin, Germany3 Travere Therapeutics, Inc.3 Insel Gruppe AG, University Hospital Bern3 Swedish Orphan Biovitrum3 European Myeloma Network B.V.3 University Hospital Tuebingen3 Juno Therapeutics, Inc., a Bristol-Myers Squibb Company3 Lifetech Scientific (Shenzhen) Co., Ltd.3 University of Leipzig3 Bayer3 Mirum Pharmaceuticals, Inc.3 University Hospital, Basel, Switzerland3 Central Institute of Mental Health, Mannheim2 Immatics US, Inc.2 MicroPort CRM2 Replimune, Inc.2 Loxo Oncology, Inc.2 Universität Münster2 Sanofi Pasteur, a Sanofi Company2 VectivBio AG2 Cook Research Incorporated2 Population Health Research Institute2 Astellas Pharma Global Development, Inc.2 Edwards Lifesciences2 University of Cologne2 Genzyme, a Sanofi Company2 Blueprint Medicines Corporation2 AO Innovation Translation Center2 BeOne Medicines2 Eikon Therapeutics2 Evangelical Hospital Düsseldorf2 Cogent Biosciences, Inc.2 LEO Pharma2 Medtronic Cardiac Ablation Solutions2 MoonLake Immunotherapeutics AG2 Occlutech International AB2 Kite, A Gilead Company2 RWTH Aachen University2 Amsterdam UMC, location VUmc2 Copenhagen University Hospital, Rigshospitalet2 Upstream Bio Inc.2 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)2 Vascutek Ltd.2 Seagen, a wholly owned subsidiary of Pfizer2 University of Hamburg-Eppendorf2 Aragon Pharmaceuticals, Inc.2 iVascular S.L.U.2 Jena University Hospital2 Immunovant Sciences GmbH2 Zealand Pharma2 Zimmer Biomet2 Federation Francophone de Cancerologie Digestive2 Octapharma2 AnaptysBio, Inc.2 Hannover Medical School2 Amber Implants B.V.2 V-Wave Ltd1 Sarepta Therapeutics, Inc.1 Stichting European Myeloma Network1 PSC Partners Seeking a Cure1 C. R. Bard1 St. Antonius Hospital Gronau1 Eva Heim1 Medtronic Neurovascular Clinical Affairs1 Michael Hopp1 Zai Lab (Shanghai) Co., Ltd.1 Inspire Medical Systems, Inc.1 Pulmonx Corporation1 Michael Hoelscher1 Aarhus University Hospital Skejby1 EBR Systems, Inc.1 Stefan Hagel1 Princess Maxima Center for Pediatric Oncology1 Terumo Europe N.V.1 Janssen-Cilag Ltd.1 University of Kiel1 Colospan Ltd.1 Marc Bosiers, MD1 Y-mAbs Therapeutics1 UMC Utrecht1 Vifor Fresenius Medical Care Renal Pharma1 CSL Behring1 Mats Heyman1 National Cancer Institute (NCI)1 University Hospital Schleswig-Holstein1 Episurf Medical Inc.1 Ludwig-Maximilians - University of Munich1 Servier Bio-Innovation LLC1 D3 Bio (Wuxi) Co., Ltd1 German Cancer Research Center1 Guardant Health, Inc.1 Pierre Fabre Medicament1 Morair Medtech, LLC1 Rhythm Pharmaceuticals, Inc.1 Infectopharm Arzneimittel GmbH1 Celldex Therapeutics1 M.A. Med Alliance S.A.1 University Hospital Goettingen1 Thomas Ernst, Prof. Dr. med.1 AtriCure, Inc.1 Syndax Pharmaceuticals1 Cardiovalve Ltd.1 Texas Scottish Rite Hospital for Children1 Medtronic Cardiac Surgery1 CytoSorbents, Inc1 Medtronic Cardiovascular1 Cardiawave SA1 University of Heidelberg Medical Center1 Aura Biosciences1 ImmunoRegister gUG1 OncoVerity, Inc.1 Janssen Pharmaceutica N.V., Belgium1 Meril Life Sciences Pvt. Ltd.1 Anthos Therapeutics, Inc.1 Helios Health Institute GmbH1 Leipzig Heart Science gGmbH1 Lohmann & Rauscher1 APrevent Biotech GmbH1 Mirati Therapeutics Inc.1 University Eye Hospital, Freiburg1 NovaGo Therapeutics AG1 Heidelberg University1 Tenax Therapeutics, Inc.1 European Foundation for Study of Chronic Liver Failure1 Liquidia Technologies, Inc.1 Goethe University1 Heinrich-Heine University, Duesseldorf1 Timo Munz1 Panbela Therapeutics, Inc.1 Biosense Webster, Inc.1 Lisette Nixon1 Ataxia Study Group1 Kliniken Beelitz GmbH1 Société des Produits Nestlé (SPN)1 LMU Klinikum1 University Hopsital Schleswig Holstein Campus Lübeck1 University Medical Center Groningen1 European Society of Cardiology1 Janssen Biotech, Inc.1 Apollo Therapeutics Ltd1 Technische Universität Dresden1 Stemline Therapeutics, Inc.1 Denali Therapeutics Inc.1 LuSeed Vascular LTD.1 Chiesi Farmaceutici S.p.A.1 Almirall, S.A.1 Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd1 Vividion Therapeutics, Inc.1 GCP-Service International West GmbH1 University Hospital of Cologne1 Heidelberg Pharma AG1 Centre Leon Berard1 Claus Lindbjerg Andersen1 ITM Solucin GmbH1 Peter Rossing1 Immunocore Ltd1 IntraBio Inc1 Women's Cancer Study Group GmbH1 Hanmi Pharmaceutical Company Limited1 IHF GmbH - Institut für Herzinfarktforschung1 Delcath Systems Inc.1 Hospital Universitari Vall d'Hebron Research Institute1 University of Luebeck1 University of Birmingham1 Dominik Paul Modest1 Research Center Borstel1 Merz Pharmaceuticals GmbH1 Viatris Innovation GmbH1 Verastem, Inc.1 Stiftung Institut fuer Herzinfarktforschung1 Crinetics Pharmaceuticals Inc.1 Aarhus University Hospital1 4TEEN4 Pharmaceuticals GmbH1 Iovance Biotherapeutics, Inc.1 Acesion Pharma1 MedSIR1 Annetine Gelijns1 Montefiore Medical Center1 AGO Study Group1 Abivax S.A.1 AIO-Studien-gGmbH1 Resilience1 Ultragenyx Pharmaceutical Inc1 Acandis GmbH1 University Medical Center Nijmegen1 RECORDATI GROUP1 Medtronic MiniMed, Inc.1 KU Leuven1 Montreal Heart Institute1 Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1 BioClin BV1 Napo Therapeutics, S.p.A.1 Otsuka Pharmaceutical Development & Commercialization, Inc.1 TransThera Sciences (Nanjing), Inc.1 Stefanie Brassen1 IO Biotech1 Weizmann Institute of Science1 Alliance for Clinical Trials in Oncology1 Kartos Therapeutics, Inc.1 EyeBiotech Ltd.1 Allergy Therapeutics1 Kailera1 Kyowa Kirin Co., Ltd.1 Medtronic1 JenaValve Technology, Inc.1 ORNND - Operating Room Nurse Network Denmark1 Medicalschool Hamburg1 Tesaro, Inc.1 Phenox GmbH1 Ottawa Heart Institute Research Corporation1 TORL Biotherapeutics, LLC1 Christian Buske1 Philips Clinical & Medical Affairs Global1 Photocure1 Miltenyi Biomedicine GmbH1 ABX advanced biochemical compounds GmbH1 Coldplasmatech1 Zura Bio Inc1 SymBio Pharmaceuticals1 TolerogenixX GmbH1 Universität Duisburg-Essen1 Steffen Paschen1 Nyxoah S.A.1 Smith & Nephew, Inc.1 Protagonist Therapeutics, Inc.1 Arcus Biosciences, Inc.1 Lexicon Pharmaceuticals1 Centre Hospitalier Universitaire de Besancon1 IRCCS Sacro Cuore Don Calabria di Negrar1 iSTAR Medical1 Edward Geissler1 University Hospital Augsburg1 Summit Therapeutics1 Instituto de Investigación Hospital Universitario La Paz1 Christian S. Meyhoff1 HighLife SAS1 University Hospital, Essen1 IRCCS San Raffaele1 Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps1 Medstar Health Research Institute1 Meyer Children's Hospital IRCCS1 Allievex Corporation1 Stichting Hemato-Oncologie voor Volwassenen Nederland1 EMD Serono Research & Development Institute, Inc.1 Nova Laboratories Limited1 CVRx, Inc.1 St. Josefs-Hospital Wiesbaden GmbH1 IDEAYA Biosciences1 Shanghai Henlius Biotech1 Deciphera Pharmaceuticals, LLC1 Stephan Baldus1 Atrial Fibrillation Network1 IGLESIAS Juan Fernando1 Norwegian University of Science and Technology1 VisionCare, Inc.1 King's College Hospital NHS Trust1 MedImmune LLC1 Kyverna Therapeutics1 Stephanie Mehl1 Swiss Cancer Institute1 Intuitive Surgical1 Forma Therapeutics, Inc.1 Atea Pharmaceuticals, Inc.1 Philogen S.p.A.1 Sebastian Probst1 European Association of Urology Research Foundation1 Beyond Batten Disease Foundation1 Cytokinetics1 Dimerix Bioscience Pty Ltd1 Shockwave Medical, Inc.1 Cardionovum GmbH1 Joseph Broderick, MD1 BioNTech Cell & Gene Therapies GmbH1 Alleviant Medical, Inc.1 Science Corporation1 Fondation Hôpital Saint-Joseph1 Shenzhen Core Medical Technology CO.,LTD.1 Karyopharm Therapeutics Inc1 Partner Therapeutics, Inc.1 Curasight1 Children's Oncology Group1 Alnylam Pharmaceuticals1 Aesculap AG1 AvenCell Therapeutics, Inc.1 Biotest1 Istituto Giannina Gaslini1 PMV Pharmaceuticals, Inc1 Tern Therapeutics, LLC1 CRISPR Therapeutics AG1 Wuerzburg University Hospital1 NVT GmbH1 Leiden University Medical Center1 Oncolytics Biotech1 Jazz Pharmaceuticals1 Deutsches Herzzentrum Muenchen1 Institut de Recherches Internationales Servier1 United Therapeutics1 Camurus AB1 Ceric Sàrl1 Contego Medical, Inc.1 SoniVie Inc.1 Gruppo Oncologico del Nord-Ovest1 Assembly Biosciences1 Okuvision GmbH1 Fundacio Puigvert1 Clear sponsor filter
Site location
Berlin117 Essen60 Hamburg54 Dresden53 Cologne49 Hanover45 Freiburg im Breisgau39 München35 Bonn33 Frankfurt32 Heidelberg29 Erlangen27 Leipzig26 Düsseldorf21 Augsburg20 Mainz19 Chemnitz19 Aachen18 Bochum16 Würzburg16 Frankfurt am Main14 Gauting14 Duisburg13 Münster13 Kiel12 Göttingen12 Amberg10 Jena10 Bielefeld10 Braunschweig10 Georgsmarienhütte10 Halle9 Tübingen9 Bad Oeynhausen8 Bad Homburg8 Marburg7 Bamberg7 Großhansdorf7 Regensburg7 Herne6 Lübeck6 Bergisch Gladbach6 Oldenburg6 Ahrensburg6 Heilbronn6 Ulm5 Brandenburg an der Havel5 Dessau5 Magdeburg5 Bad Berka5 Esslingen am Neckar5 Homburg5 Bremen5 Gütersloh5 Aschaffenburg5 Karlsruhe4 Nuremberg4 Bad Saarow4 Falkensee4 Immenhausen4 Mannheim4 Deggendorf4 Erfurt4 Dortmund4 Frankfurt A. Main3 Cottbus3 Mettmann3 Kirchheim3 Mönchengladbach3 Giessen3 Bad Nauheim3 Greifswald3 Löwenstein3 Ansbach3 Brandenburg3 Berlin-Zehlendorf3 Bechhofen3 Darmstadt3 Nürtingen2 Ravensburg2 Kaiserslautern2 Kassel2 Mainz Am Rhein2 Trier2 Bendorf2 Coswig2 Bottrop2 Wiesbaden2 Konstanz2 Munich2 Gerlingen2 Bad Bramstedt2 Moers2 Baden-Baden2 Bad Nenndorf2 Elsterwerda2 Damme2 Esslingen a.N.2 Bünde2 Rostock2 Langen2 Gera2 Daaden1 Eisenach1 Bayern1 Paderborn1 Minden1 Solingen1 Haltern am See1 Rosenheim1 Fulda1 Bautzen1 Borna1 Heinsberg1 Friedrichsthal1 Villingen-Schwenningen1 Heidenheim1 Schorndorf1 Stuttgart1 Bremenhaven1 Celle1 Schleswig-Holstein1 D Sseldorf1 Altenburg1 Kempten1 Apolda1 Bad Reichenhall1 Balingen1 Bad Mergentheim1 Cloppenburg1 Bernau bei Berlin1 Coburg1 Goslar1 Sankt Augustin1 Detmold1 Leverkusen1 Böblingen1 Osnabrück1 Rotenburg (Wümme)1 Bad Oldesloe1 Buxtehude1 Dachau1 Gifhorn1 Schwerin1 Wuppertal1 Bad Bevensen1 Bad Friedrichshall1 Gladbeck1 Velbert1 Deggingen1 Augsburg, by1 Flensburg1 Mühlheim An Der Ruhr1 Bayreuth1 Witten1 Auerbach1 Dessau-RoBlau1 Ludwigsburg1 Gelsenkirchen1 Esslingen A. N.1 Alsfeld1 Brilon1 Bruchsal1 Immenstadt im Allgäu1 D Ren1 Herrsching am Ammersee1 L Rrach1 M Nchen1 N Rnberg1 Neustadt Am R Benberge1 Saarbr Cken1 Sindelfinden1 Hemer1 Bad Abbach1 Göppingen1 Hagen1 Landsberg1 Bad Doberan1 Sendenhorst1 Neu-Ulm1 Neuss1 Koblenz Am Rhein1 Potsdam1
All 183 locations
Target enrolment
to

Trials with a site in Hamburg

54 of 5087 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
AstraZeneca
Phase 3
750
Berlin, Dresden, Essen, Freiburg im Breisgau, Hamburg, Leipzig, München, Oldenburg
2026-09-24
Recruiting
AstraZeneca
Phase 3
1,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-20
Recruiting
AstraZeneca
Phase 3
2,500
Berlin, Bochum, Bünde, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2026-08-19
Recruiting
AstraZeneca
Phase 3
600
Ahrensburg, Berlin, Bochum, Gladbeck, Hamburg, Hanover, Karlsruhe, Leipzig
2026-08-12
Recruiting
AstraZeneca
Phase 3
915
Bochum, Bonn, Dresden, Duisburg, Frankfurt am Main, Hamburg, Hanover, Herne
2026-07-16
Recruiting
AstraZeneca
Phase 3
900
Bad Oeynhausen, Berlin, Brandenburg an der Havel, Chemnitz, Duisburg, Erlangen, Frankfurt, Hamburg
2026-07-06
Recruiting
AstraZeneca
Phase 3
4,500
Bad Oeynhausen, Bochum, Cologne, Dresden, Falkensee, Gera, Hamburg, Leipzig
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig
2026-06-26
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Bonn, Coswig, Essen, Freiburg im Breisgau, Fulda, Giessen, Hamburg, Hanover
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
Berlin, Cologne, Essen, Hamburg, Heidelberg, Homburg, München, Münster
2026-06-11
Recruiting
AstraZeneca
Phase 3
245
Bad Abbach, Hamburg, Mainz, München
2026-04-13
Recruiting
AstraZeneca
Phase 3
508
Berlin, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hamburg, Leipzig, Mainz
2026-02-23
Recruiting
A Study of AZD0120 in Autoimmune Diseases
NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1/2
27
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
2026-01-09
Recruiting
AstraZeneca
Phase 3
1,100
Berlin, Bonn, Detmold, Dresden, Düsseldorf, Essen, Frankfurt am Main, Hamburg
2025-12-29
Recruiting
AstraZeneca
Phase 2
320
Bad Doberan, Berlin, Hamburg, Sendenhorst
2025-12-15
Recruiting
AstraZeneca
Phase 2
230
Augsburg, Berlin, Cologne, Frankfurt, Hamburg, Jena, Leipzig, München
2025-12-10
Recruiting
AstraZeneca
Phase 3
1,100
Aachen, Berlin, Bonn, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Hamburg
2025-12-04
Recruiting
AstraZeneca
Phase 3
800
Amberg, Chemnitz, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2025-08-01
Active, closed
AstraZeneca
Observational
2,000
Hamburg
2025-04-17
Active, closed
AstraZeneca
Phase 2
82
Berlin, Dresden, Essen, Hamburg, Marburg
2025-03-12
Active, closed
AstraZeneca
Phase 3
768
Berlin-Zehlendorf, Essen, Georgsmarienhütte, Großhansdorf, Hamburg, Löwenstein, Nuremberg
2024-10-04
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca
Phase 2
257
Cologne, Frankfurt, Gauting, Großhansdorf, Hamburg, Heidelberg, Mainz, Münster
2024-08-22
Recruiting
AstraZeneca
Phase 3
620
Berlin, Bonn, Cologne, Dresden, Frankfurt, Freiburg im Breisgau, Göttingen, Hamburg
2024-08-12
Recruiting
AstraZeneca
Phase 3
1,018
Berlin, Deggendorf, Düsseldorf, Göttingen, Hamburg, Heidelberg, Jena, Karlsruhe
2024-08-07
Active, closed
AstraZeneca
Phase 3
594
Berlin, Frankfurt, Göttingen, Hamburg, Heidelberg, Heilbronn, Leipzig, Marburg
2024-03-04
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca
Phase 1/2
255
Berlin, Cologne, Düsseldorf, Essen, Frankfurt, Freiburg im Breisgau, Halle, Hamburg
2023-12-29
Recruiting
AstraZeneca
Phase 3
1,145
Berlin, Erlangen, Essen, Freiburg im Breisgau, Greifswald, Hamburg, Hanover, Leipzig
2023-12-14
Recruiting
AstraZeneca
Phase 1/2
226
Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
2023-12-05
Active, closed
AstraZeneca
Phase 3
760
Berlin, Bonn, Dortmund, Dresden, Erlangen, Esslingen A. N., Frankfurt, Hamburg
2023-12-04
Active, closed
AstraZeneca
Phase 3
863
Berlin, Bochum, Cologne, Essen, Gauting, Georgsmarienhütte, Großhansdorf, Hamburg
2023-11-09
Recruiting
AstraZeneca
Phase 3
800
Berlin, Bonn, Hamburg, Leipzig
2023-09-22
Active, closed
AstraZeneca
Phase 3
1,350
Bad Berka, Berlin, Frankfurt A. Main, Gauting, Gütersloh, Hamburg, Kassel, Kiel
2022-12-29
Recruiting
AstraZeneca
Phase 3
3,527
Augsburg, Berlin, Cologne, Hamburg, Hanover, Kiel, Leverkusen, Marburg
2022-12-13
Active, closed
PASS of Paediatric Patients Initiating Selumetinib
NCT05388370Neurofibromatosis Type 1
AstraZeneca
Observational
124
Dresden, Duisburg, Hamburg, Hanover, München, Tübingen
2022-05-23
Active, closed
AstraZeneca
Phase 3
760
Bonn, Chemnitz, Dresden, Düsseldorf, Frankfurt, Göttingen, Hamburg, Hanover
2022-03-28
Active, closed
AstraZeneca
Phase 1/2
36
Hamburg, München, Tübingen
2022-01-21
Active, closed
AstraZeneca
Phase 3
145
Hamburg, Tübingen, Würzburg
2021-11-19
Active, closed
AstraZeneca
Phase 3
148
Hamburg, Hanover, München, Ulm
2021-10-28
Active, closed
AstraZeneca
Phase 3
927
Augsburg, Berlin, Erlangen, Hamburg, Heidelberg, Kiel, Leipzig, Mönchengladbach
2021-10-25
Active, closed
AstraZeneca
Phase 3
506
Berlin, Dresden, Erlangen, Essen, Frankfurt, Hamburg, Hanover, Kiel
2021-06-22
Active, closed
AstraZeneca
Phase 3
1,157
Berlin, Dresden, Erlangen, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Heidelberg
2021-04-26
Active, closed
AstraZeneca
Phase 3
957
Berlin, Dresden, Frankfurt, Hamburg, Heidelberg, Heilbronn, Jena, Mainz Am Rhein
2020-11-17
Active, closed
AstraZeneca
Phase 3
1,012
Berlin, Duisburg, Hamburg, Herne, Mettmann, Münster, Nuremberg, Nürtingen
2020-07-13
Active, closed
AstraZeneca
Phase 2
452
Frankfurt, Hamburg, Leipzig, Mannheim, München
2020-06-03
Active, closed
AstraZeneca
Phase 3
818
Dresden, Erlangen, Essen, Frankfurt, Gelsenkirchen, Hamburg, Hanover, Heidelberg
2020-04-16
Active, closed
AstraZeneca
Phase 3
140
Bamberg, Freiburg im Breisgau, Hamburg, Kirchheim, Lübeck
2019-10-29
Active, closed
AstraZeneca
Phase 2
273
Dresden, Frankfurt am Main, Hamburg, Hanover, Leipzig, München, Witten
2018-03-07
Active, closed
AstraZeneca
Phase 3
1,186
Berlin, Essen, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Immenhausen, Mainz
2017-06-01
Active, closed
AstraZeneca
Phase 3
987
Aachen, Berlin, Gauting, Gera, Hamburg, Heidelberg, Mainz, Regensburg
2017-03-27
Active, closed
AstraZeneca
Phase 3
1,118
Aachen, Bad Berka, Berlin, Freiburg im Breisgau, Gauting, Hamburg, Heidelberg, Hemer
2015-07-21
Rows per page Showing 1–54 of 54
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 November 2026. https://priyalifescience.com/clinical-trials-germany/city/hamburg

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,087 studies in total at the last sync on 20 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 54 of those studies with a site in Hamburg that also match the filters currently applied.

How many clinical trials are recruiting in Hamburg?

27 of the 54 studies on this page are recruiting new participants as of the 20 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hamburg), 54 studies
PhaseStudiesRecruitingShare
Phase 3392072.2%
Phase 29416.7%
Phase 1/2437.4%
Observational203.7%

Most active sponsors

Lead sponsors with the most studies (Hamburg)
Lead sponsorStudiesRecruiting
AstraZeneca5427
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.